The world’s first lung cancer vaccine, BNT116, developed by BioNTech using mRNA technology, has entered clinical trials in seven countries, targeting non-small cell lung cancer (NSCLC).

The Phase 1 study, involving 130 patients across 34 sites, tests safety and immune response, aiming to prevent recurrence and improve survival.

Success could revolutionize cancer treatment with proactive immunotherapy.